Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

David A. Wilcox PhD
Associate Professor
Department of Pediatrics
Division of Hematology/Oncology

OFFICE ADDRESS:
MACC Fund Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226

CITIZENSHIP:  USA

EDUCATION:
1987 BS Chemistry, University of Wisconsin, Platteville, WI
1994 PhD, Cell Biology, Medical College of Wisconsin, Milwaukee, WI

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
6/1986 - 8/1986 Summer Intern, Wisconsin State Crime Lab, University of Wisconsin, Milwaukee, WI
7/1986 Arson Investigator Training Program, FBI Bomb Data Program, Racine, WI
6/1987 - 6/1988 Volunteer, Emergency Room, St. Mary's Hospital, Racine, WI
6/1988 - 9/1988 Research Assistant, Psychiatry, Medical College of Wisconsin, Milwaukee, WI
9/1988 - 8/1989 Research Assistant, Cellular Biology and Anatomy, Medical College of Wisconsin, Milwaukee, WI
9/1989 - 6/1994 Graduate Student, Cellular Biology and Anatomy, Medical College of Wisconsin/Blood Research Institute of the BloodCenter of Wisconsin, Milwaukee, WI
7/1994 - 4/1999 Postdoctoral Fellow, Medicine and Pharmacology, Medicine and Pharmacology, University of North Carolina, Chapel Hill, NC

FACULTY APPOINTMENTS:
1999 - 2005 Assistant Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI
1999 - Present Associate Investigator, Blood Research Institute, The BloodCenter of Wisconsin, Milwaukee, WI
2005 - 2008 Research Associate Professor, Pediatrics, Medical College of Wisconsin, Milwaukee, WI
2008 - Present Associate Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI

AWARDS AND HONORS:
1992 Travel Award, American Heart Association
1993 Travel Award, American Society of Hematology
1994 - 1995 National Research Service Award, National Institutes of Health
1996 Travel Award, American Society of Hematology
1997 Travel Award, American Society of Hematology
1998 Travel Award, American Society of Hematology
1999 Young Investigator Award, International Society for Thrombosis and Haemostasis
2003 Invited Session Chair, International Society of Thrombosis and Haemostasis
3/2005 Invited Discussion Leader, Gordon Research Conference on Cell Biology of Megakaryocytes and Platelets, Santa Barbara, CA
2/2011 Best Abstract in Basic Research, American Society for Bone Marrow Transplant, Honolulu, HI

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
American Society of Gene Therapy (ASGCT) (Member)
International Society of Thrombosis and Haemostasis (ISTH) (Member)
American Society of Hematology (ASH) (Member)
American Heart Association (Scientific Council Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
1999 - Present Thrombosis and Haemostasis
2002 - Present Journal of Thrombosis and Haemostasis
2003 - Present Blood
2003 - Present Biology of Blood and Marrow Transplantation
2006 - Present Translational Research
2007 - Present Platelets
2008 - Present ILAR Journal
2009 - Present Human Gene Therapy
2010 - Present Gene Therapy
2011 - Present Haemophilia
2011 - Present Thrombosis Research
2011 - Present Proceedings of The National Academy of Sciences
2012 - Present Indian Journal of Sexually Transmitted Diseases and AIDS
2012 - Present PLOS
2012 - Present European Journal of Human Genetics
2013 - Present Haematologica Journal

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2004 Ad Hoc Reviewer, Study Section for Hemostasis and Thrombosis, National Institute of Health (NIH)
2005 Ad Hoc Reviewer, Haemophilia Research United Kingdom
2006 Ad Hoc Reviewer, Association Francaise Contre Les Myopathies, France
2007 Ad Hoc Reviewer, Study Section for Hemostasis and Thrombosis, National Institute of Health (NIH)
2007 Ad Hoc Reviewer, Study Section for Clinical Hematology, National Institute of Health (NIH)
2008 Ad Hoc Reviewer, Study Section for Hemostasis and Thrombosis, National Institute of Health (NIH)
2/2009 - 10/2009 Ad Hoc Reviewer, Study Section for Hemostasis and Thrombosis (Feb., National Institute of Health (NIH)
2009 Ad Hoc Reviewer, Study Section for Hemostasis and Thrombosis (Stimulus Grants), National Institute of Health (NIH)
2010 Collaborator, Thrombogenomics Committee, Glanzmann Thrombasthenia Section
3/2011 Abstract Reivewer, International Society of Thrombosis and Haemostasis
7/2011 Ad Hoc Reviewer, Study Section for Viruses and Immunity PPG, National Institute of Health (NIH)
10/2011 Ad Hoc Reviewer, Study Section for Hemostasis and Thrombosis, National Institute of Health (NIH)
2013 - Present Abstract Revewer, American Society of Gene and Cell Therapy
2013 Abstract Reivewer, Iternational Society of Thrombosis and Haemostasis
2013 - Present Ad Hoc Reviewer, N ll-1 Study Section for Vascular Biology

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Therapeutic Expression of a Platelet-Specific Integrin (Years 1-5)
Source:
NIH NHLB R01-068138
Role:
Principal Investigator (50% effort)
Dates:
4/1/2002 - 6/30/2012
Direct Funds:
$2,085,587 ($250,000/year In-No-Cost-Extension)
 
Non-Peer Review
Title:
Glanzmann Thrombasthenia and Hemophilia A Human and Animal Research
Source:
Children's Research Institute (Private Donor work Specific for Wilcox Lab)
Role:
Principal Investigator
Dates:
2008 - 2015
Direct Funds:
$1,800,000 ($350,000/year)
 
Title:
Lineage Specific Gene Expression
Source:
MACC Fund
Role:
Principal Investigator
Dates:
7/1/2010 - 6/30/2012
Direct Funds:
$832,159 ($81,184.69/year)
 
Pending
Peer Review
Title:
Recombinant Platelet Antigen Stable Cell Lines
Source:
Hologic/Gene-Probe
Role:
Principal Investigator
Dates:
7/1/2014 - 6/30/2015
 
Prior
Peer Review
Title:
Cell & Molecular Biology of the Human Platelet Fibrinogen Receptor
Source:
American Heart Association - Wisconsin Affiliate
Role:
Predoctoral Fellowship (90% effort)
Dates:
7/1/1992 - 6/30/1993
Direct Funds:
$20,000
 
Title:
Cell & Molecular Biology of the Human Platelet Fibrinogen Receptor
Source:
American Heart Association - Wisconsin Affiliate
Role:
Predoctoral Fellowship (90% effort)
Dates:
7/1/1993 - 6/30/1994
Direct Funds:
$20,000
 
Title:
Platelet-Specific Expression of a Functional Human Fibrinogen Receptor
Source:
American Heart Association - North Carolina Affiliate
Role:
Postdoctoral Fellowship (%100 effort)
Dates:
7/1/1995 - 6/30/1997
Direct Funds:
$60,000
 
Title:
Molecular and Cellular Mechanisms in Transfusion Medicine
Source:
NIH NHLB HL44612-15
Role:
Collaborator, Program Project Grant (10% effort)
Dates:
5/1/2000 - 4/30/2005
Direct Funds:
$32,000
 
Title:
Therapeutic Expression of a Platelet-Specific Integrin
Source:
Medical College of Wisconsin New Faculty Grant
Role:
Principle Investigator (50% effort)
Dates:
5/25/2001 - 4/30/2002
Direct Funds:
$12,500
 
Title:
Therapeutic Expression of a Platelet-Specific Integrin
Source:
American Heart Association - Northland Affiliate
Role:
Principal Investigator, Beginning Grant-in-Aid (50% effort)
Dates:
7/1/2001 - 6/30/2003
Direct Funds:
$80,000 (Funding Relinquished 4/1/02, Due to Overlap with NIH Grant)
 
Title:
Lineage-Specific Gene Expression
Source:
Children's Hospital Foundation
Role:
Principal Investigator (50% effort)
Dates:
7/1/2001 - 6/30/2003
Direct Funds:
$66,000
 
Title:
Structure and Function of TSP1 in Acute Lung Injury
Source:
NIH NHLB R01-071618
Role:
Collaborator (10% effort)
Dates:
11/1/2004 - 10/31/2008
Direct Funds:
$32,000 (Funding Relinquished 11/01/04, PI Relocated to University of Colorado)
 
Title:
Molecular and Cellular Mechanisms in Transfusion Medicine
Source:
NIH NHLB HL44612-15
Role:
Collaborator, Program Project Grant (5% effort)
Dates:
12/1/2005 - 11/30/2010
Direct Funds:
$16,000
 
Title:
Platelet-Specific Gene Therapy and its Potential for Correcting Hemophilia
Source:
American Heart Association - Greater Midwest Affiliate
Role:
Grant-in-Aid (20% effort)
Dates:
7/1/2007 - 6/30/2009
Direct Funds:
$132,000
 
Title:
Therapeutic Expression of a Platelet-Specific Integrin
Source:
NIH NHLB R01-068138
Role:
Principal Investigator (40% effort)
Dates:
7/1/2007 - 6/30/2011
Direct Funds:
$1,385,587
 
Non-Peer Review
Title:
Glanzmann Thrombasthenia Research
Source:
Glanzmann's Research Foundation
Role:
Principal Investigator
Dates:
7/1/2001 - 6/30/2011
Direct Funds:
$189,000 ($10,000/year)
 
Source:
Glanzmann Research Fund
Dates:
2004
Direct Funds:
$2,500
 
Title:
Glanzmann Thrombasthenia Research
Source:
Cure Glanzmann's Foundation
Role:
Principal Investigator
Dates:
7/1/2010 - 6/30/2011
Direct Funds:
$4,410 ($1000/year)
 
INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Regional
1. MACC Fund Scientific Symposium, Wisconsin Institute for Medical Research, 12/2009
 
National
1. Targeting Gene Therapy for Inherited Hematological Disorders and The Molecular Basis for Gene Therapy Using Hematopoietic Stem Cells, BMS Seminar/Goodwin Lecturer, Auburn University, AL, 4/2002
2. Invited Presentation, Annual Fund Raiser for Glanzmann Thrombasthenia Research, Augusta, GA, 2002 - 2008
3. Invited Discussion Leader, Gordon Research Conference on Cell Biology of Megakaryocytes and Platelets, Santa Barbara, CA , 3/2005
4. Therapeutic expression of IIb3 in murine and canine models of Glanzmann thrombasthenia, Subcommittee Meeting on Platelets at the American Society of Hematology Annual Meeting, Atlanta, GA, 12/2005
5. Hematopoietic Stem Cell Gene Therapy for Inherited Platelet Bleeding Disorders, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3/2008
6. Targeting Therapeutic Agents to Platelets, Novo Nordisk Corporation, East Brunswick, NJ, 4/2008
7. Gene Therapy for Platelets Disorders, Platelets 2008 International Symposium, Woods Hole, MA, 10/2008
8. Department of Medicine, Rockefeller University, 11/2008
9. Special Symposium for Thrombosis & Hemostasis, American Society of Hematology Annual Meeting, San Francisco, CA, 12/2008
10. US House of Representatives, Congressman Gingrey, R-Georgia and Deputy Director NHLBI-NIH, Dr. Susan Shurdin, 6/2009
11. Seminar, Auburn University, AL, 3/2011
12. Seminar, Transfusion Medicine Grand Rounds at the Brigham and Women's Hospital and Children’s Hospital, Boston, MA, 11/2011
13. Seminar, Indiana University School of Medicine, IN, 12/2011
14. Division of Hematology 2010-2011 Seminars at The Children's Hospital of Philadelphia, University of Philadelphia, Philadelphia, PA, 12/2011
 
PEER REVIEWED WORKSHOPS/PRESENTATIONS:
National
1. Wilcox DA, Wautier JL, Pidard D, Newman PJ, An amino acid substitution within the fourth calcium-binding region of GPIIb results in degradation of the integrin GPIIb-IIIa and type I glanzmann thrombasthenia, Annual Meeting of the American Heart Association, 1992
2. Wilcox DA, Gill J, Newman PJ, Glanzmann thrombasthenia resulting from a single amino acid substitution flanking the fibrinogen -chain dodecapeptide-binding domain on GPIIb, American Society of Hematology (ASH) Annual Meeting, 12/1993
3. Wilcox DA, Hodivala-Dilke KM, Hynes RO, White GC II, Of mice and men: detection of a functional murine IIb3 heterodimer complex on the surface of megakaryocytes derived from retrovirus transduced bone marrow cells from 3-knockout mice, American Society of Hematology (ASH) Annual Meeting, 12/1998
4. Use of IIb Promoter in Retroviral Constructs, Gordon Research Conference on Hemostasis, Plymouth, NH, 7/2000
5. Wilcox DA, Hodivala-Dilke KM, Johnson BD, Hynes RO,White GC II, Therapeutic expression of a platelet-specific integrin, IIb3, American Society for Gene Therapy Annual Meeting, 2003
6. Wilcox DA, Fang J, Jensen ES, Du LM, Boudreaux MK, Thereapeutic expression of a platelet-specific integrin restores hemostasis in dogs with glanzmann thrombasthenia, American Society of Gene Therapy Annual Meeting, Seattle, WA, 6/2007
7. Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC II, Montgomery RR, EM localization and agonist-induced release of human FVIII from megakaryocytes transduced with a FVIII transgene, American Society of Hematology Annual Meeting, San Diego, CA, 12/2009
8. Du LM, Franck HWG, Merricks EP, Nurded P, Jensen ES, Haberichter SL, Hawkins TB, Jacobi PM, Fang J, Koukouritaki SB, Nurden AT, Shi Q, Montgomery RR, Wilcox DA, Gene therapy targeting synthesis of coagulation factor viii in platelets reduces bleeding in canine hemophilia a, Best Abstract in Basic Research at the American Society for Bone Marrow Transplant Annual Meeting, Hawaii, 2/2011
 
COMMITTEE SERVICE:
Medical College
2000 - 2001 Member, Search Committee for Candidates for Medical College of Wisconsin Faculty in Hematopoietic Stem Cell Gene Therapy, Medical College of Wisconsin
2000 - 2001 Member, Search Committee Candidates for Medical College of Wisconsin/Blood Research Institute Joint Recruitment for Faculty in Stem Cell Biology, Medical College of Wisconsin
2002 - Present Member, Fellowship Selection Committee, Hematology/Oncology/BMT, Pediatrics, Medical College of Wisconsin
2004 - Present Member, Research Task Force Committee, Pediatrics, Medical College of Wisconsin
2004 - 2006 Voting Member, Institutional Animal Care and Use Committee (IACUC), Medical College of Wisconsin
2006 Co-Chairman During Summer, Institutional Animal Care and Use Committee (IACUC), Medical College of Wisconsin
2006 - Present Chairman, Advisory Board for the Lentivirus Core Facility, Medical College of Wisconsin
2007 Member, Insitutional Animal Care and Use Committee (IACUC) Committee to β-test the online protocol for Animal Research, Medical College of Wisconsin
2007 - 2011 Member, Biosafety Committee, Medical College of Wisconsin
 
Hospital
2000 - 2001 Member, Scientific Review Committee, Children's Hospital Foundation
2006 Member, Scientific Review Committee, Children's Hospital Foundation
 
MEDICAL COLLEGE TEACHING ACTIVITIES:
Continuing Medical Education
1999 Department of Pediatrics, Seminar on Megakaryocyte-Targeted Gene Therapy for Inherited Hematological Disorders
2000 Department of Biochemistry, Signal and Gene Expression Group, Seminar on Gene Therapy for Platelet Disorders
2001 Department of Biochemistry, Signal and Gene Expression Group, Seminar on Gene Therapy for Platelet Disorders
2002 Biomedical Resource Center, Research Training Seminar
2003 Blood Research Institute, Seminar on Targeting Gene Therapy to Specific Hematopoietic Lineages
2003 Department of Pediatrics, Seminar on Targeting Gene Therapy to Specific Hematopoietic Lineages
2005 Department of Biochemistry, Signal and Gene Expression Group, Seminar on Gene Therapy for Inherited Bleeding Disorders
2006 Department of Pediatrics, Seminar on Gene Therapy for Inherited Bleeding Disorders
2006 Department of Physiology, Seminar on Gene Therapy for Inherited Bleeding Disorders
2006 Hematology/Oncology Medical Fellows Lecture Series, Platelet Disorders
2007 Hematology/Oncology Medical Fellows Lecture Series, Platelet Disorders
10/2008 Blood Research Institute, Presentation to Scientific Review Committee
12/2008 MACC Fund, Presentation to Scientific Review Committee
2008 Invited Presentation, Children's Hospital President Council Meeting, 2002 PIR Award Lineage Specific Gene Expression
2008 Pediatric Hematology/Oncology Medical Fellows Lecture Series, Platelet Disorders
2008 Children's Research Institute Noon Academic Conference, Seminar on Hematopoietic Stem Cell Gene Therapy for Inherited Bleeding Disorders
2008 Children's Research Institute, Seminar on Gene Therapy for Inherited Bleeding Disorders
10/2011 Blood Research Institute, Presentation to Scientific Review Committee
 
EXTRAMURAL TEACHING (e.g. at Marquette, UWM, etc.):
Continuing Medical Education
2/2008 University of Wisconsin-Milwaukee, IDepartment of Biological Sciences Colloquim Series Presenation - Gene Therapy for Inherited Platelet Bleeding Disorders
 
MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Postdoctoral Students
Runqui Jiang, Medical College of Wisconsin, 3/1/2009 - 9/29/2009 Invited Foreign Dissertation Advisor
Yoshinori Nishijima, Medical College of Wisconsin, 4/25/2011 - Present Mentor for Postdoctoral Fellow
 
EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
High School Students
High School Summer Student , Medcial College of Wisconsin, 7/7/2010 - 8/23/2010 Mentor
 
Postdoctoral Students
Lisebeth DeWaele, Katholieke University of Leuven, Belgium, 5/6/2009 Invited Dissertation Committee Defense
 
PROGRAMMATIC DEVELOPMENTS:
 
Research Programs
2011 Co-inventor, Methods and Compositions for Enhancing Cell Adhesion Properties; U.S. Patent Application No. 11/118,712; International No. PCT/US2005/015120
 
 
 

BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Liu S, Wilcox DA, Sieber-Blum M, Wong-Riley M Developing neural crest cells in culture: correlation of cytochrome oxidase activity with SSEA-1 and dopamine-beta-hydroxylase immunoreactivity. Brain Res. 1990 Dec 10;535(2):271-80
2. Wilcox DA, Wautier JL, Pidard D, Newman PJ A single amino acid substitution flanking the fourth calcium binding domain of alpha IIb prevents maturation of the alpha IIb beta 3 integrin complex. J Biol Chem. 1994 Feb 11;269(6):4450-7
3. Wilcox DA, Paddock CM, Lyman S, Gill JC, Newman PJ Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domains of GPIIb. Role of the GPIIb amino terminus in integrin subunit association. J Clin Invest. 1995 Apr;95(4):1553-60
4. Wilcox DA, Olsen JC, Ishizawa L, Griffith M, White GC 2nd Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9654-9
5. Shiraga M, Ritchie A, Aidoudi S, Baron V, Wilcox D, White G, Ybarrondo B, Murphy G, Leavitt A, Shattil S Primary megakaryocytes reveal a role for transcription factor NF-E2 in integrin alpha IIb beta 3 signaling. J Cell Biol. 1999 Dec 27;147(7):1419-30
6. Wilcox DA, Olsen JC, Ishizawa L, Bray PF, French DL, Steeber DA, Bell WR, Griffith M, White GC 2nd Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood. 2000 Jun 15;95(12):3645-51
7. Shi Q, Wilcox DA, Fahs SA, Kroner PA, Montgomery RR Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. Mol Genet Metab. 2003 May;79(1):25-33
8. Wilcox DA, White GC 2nd Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia. J Thromb Haemost. 2003 Nov;1(11):2300-11
9. Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, Poncz M Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood. 2003 Dec 1;102(12):4006-13
10. Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Haemost. 2003 Dec;1(12):2477-89
11. Niemeyer GP, Boudreaux MK, Goodman-Martin SA, Monroe CM, Wilcox DA, Lothrop CD Jr Correction of a large animal model of type I Glanzmann's thrombasthenia by nonmyeloablative bone marrow transplantation. Exp Hematol. 2003 Dec;31(12):1357-62
12. Shi Q, Wilcox DA, Morateck PA, Fahs SA, Kenny D, Montgomery RR Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX. J Thromb Haemost. 2004 Nov;2(11):1989-97
13. Fang J, Hodivala-Dilke K, Johnson BD, Du LM, Hynes RO, White GC 2nd, Wilcox DA Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood. 2005 Oct 15;106(8):2671-9
14. Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest. 2006 Jul;116(7):1974-82
15. Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost. 2007 Feb;5(2):352-61
16. Ghevaert C, Wilcox DA, Fang J, Armour KL, Clark MR, Ouwehand WH, Williamson LM Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. J Clin Invest. 2008 Aug;118(8):2929-38
17. Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, Weiler H, Montgomery RR Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood. 2008 Oct 1;112(7):2713-21
18. Mendoza SA, Fang J, Gutterman DD, Wilcox DA, Bubolz AH, Li R, Suzuki M, Zhang DX TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress. Am J Physiol Heart Circ Physiol. 2010 Feb;298(2):H466-76
19. Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling. Blood. 2011 May 5;117(18):4946-52
20. Fang J, Jensen ES, Boudreaux MK, Du LM, Hawkins TB, Koukouritaki SB, Cornetta K, Wilcox DA Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9583-8
21. Zheng X, Zinkevich NS, Gebremedhin D, Gauthier KM, Nishijima Y, Fang J, Wilcox DA, Campbell WB, Gutterman DD, Zhang DX Arachidonic Acid-Induced Dilation in Human Coronary Arterioles: Convergence of Signaling Mechanisms on Endothelial TRPV4-Mediated Ca2+ Entry. J Am Heart Assoc. 2013;2(3):e000080
22. Fang J, Nurden P, North P, Nurden AT, Du LM, Valentin N, Wilcox DA C560Rβ3 caused platelet integrin αII b β3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. J Thromb Haemost. 2013 Jun;11(6):1163-71
23. Kuether EL, Schroeder JA, Fahs SA, Cooley BC, Chen Y, Montgomery RR, Wilcox DA, Shi Q Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. J Thromb Haemost. 2012 Aug;10(8):1570-80
24. Nurden AT, Pillois X, Wilcox DA Glanzmann Thrombasthenia: State of the Art and Future Directions. Semin Thromb Hemost. 2013 Aug 8:
25. Sullivan SK, Mills JA, Koukouritaki SB, Vo KK, Lyde RB, Paluru P, Zhao G, Zhai L, Sullivan LM, Wang Y, Kishore S, Gharaibeh EZ, Lambert MP, Wilcox DA, French DL, Poncz M, Gadue P High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood. 2013 Dec 13:
26. Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Merricks E, Raymer RA, Fang J, Koukouritaki SB, Jacobi PM, Hawkins TB, Cornetta K, Shi Q, Wilcox DA Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun. 2013;4:2773
27. Schroeder JA, Chen Y, Fang J, Wilcox DA, Shi Q In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low MOI. J Thromb Haemost. 2014 Jun 16:
 
Books, Chapters, and Reviews
1. Wilcox, D. A., White II, G.C. Gene therapy for platelet disorders. In: Platelets. A.D. Michelson (ed.), Academic Press, San Diego, Chapter 61: 927-37, 2002.
2. Wilcox, D.A. White II, G.C. Gene therapy for platelet disorders: studies with glanzmann's thrombasthenia. Journal of Thrombosis and Haemostasis. 1: 2300-2311, 2003.
3. Wilcox, D. A., White II, G.C: Gene therapy for platelet disorders. In: Platelets. Second Edition, A.D. Michelson (ed.), Academic Press, San Diego, Chapter 71: 1313-1325, 2007.
 
Editorials, Letters to Editor, Other
1. Co-inventor , Methods and Compositions for Enhancing Cell Adhesion Properties. U.S. Patent Application No. 11/118,712; International No. PCT/US2005/015120. U.S. Patent No. 7,939,326 awarded May 10, 2011
 
Abstracts
1. Wilcox DA, Sieber-Blum M. Monoclonal antibody, B-1A11, to a cell surface epitope recognizes a subpopulation of early neural crest cells. Society for Neuroscience Abstracts. 1989;15 a:352.3
2. Wilcox DA, Wautier JL, Pidard D, Newman PJ. An amino acid substitution within the fourth calcium-binding region of GPIIb results in degradation of the integrin GPIIb-IIIa and type I glanzmann thrombasthenia. Circulation. 1992;86 a:2713
3. Valentin N, Wilcox DA, Newman PJ. Disruption of the GPIIIa cys5-cys435 disulfide bonded-loop: effects on the PlA1 epitope and GPIIb-IIIa complex formation. Blood. 1993;82 a:826
4. Wilcox, D. A., Gill, J., and Newman, P. J. Glanzmann thrombasthenia resulting from a single amino acid substitution flanking the fibrinogen gamma-chain dodecapeptide-binding domain on GPIIb, Blood. 82 a:824, 1993.
5. Wilcox, D. A., Olsen, J. C., and White II, G.C. Retrovirus mediated gene therapy for glanzmann thrombasthenia: tissue-specific transcription and synthesis of the GPIIIa PlA2 alloantigen within cells homozygous for PlA1, Blood. 88 a:108, 1996.
6. Wilcox, D. A., Olsen, J. C., Ishizawa, L., Bray, P.F., French, D.L., Bell, W.R., Griffith, M., and White II, G.C. Phenotypic correction of Glanzmann's thrombasthenia following megakaryocyte-targeted synthesis of the integrin β3-subunit, Blood. 90 a:1236, 1997.
7. Wilcox, D. A., Hodivala-Dilke, K.M., Hynes, R.O., and White II, G.C. Of mice and men: detection of a functional murine IIb3 heterodimer complex on the surface of megakaryocytes derived from retrovirus transduced bone marrow cells from β3-knockout mice, Blood. 92 a:2885, 1998.
8. Wilcox, D. A., Hodivala-Dilke, K.M., Steeber, D.A., Shattil, S.J., Hynes, R.O., and White II, G.C. Expression of a functional murine αIIβ-human β3 heterodimer complex on the surface of megakaryocytes derived from β3 3-knockout mice, Thrombosis and Haemostasis. 82 a:1168, 1999.
9. Shiraga, M., Richie, A., Aidoudi, S., Baron, V., Wilcox, D., White, G., Ybarrando, B., Murphy, G., Leavitt, A., and Shattil, S.A. A role for transcription factor NF-E2 in the regulation of integrin alphaIIb-beta3 signaling, Blood. 94 a:2750, 1999.
10. Wilcox, D.A., Rosenberg, J.B., White II, G.C., and Montgomery, R.R. Factor VIII (FVIII) trafficks to megakaryocyte alpha-granules following retroviral transduction of human CD34+ cells, Blood. 94 a:1962, 1999.
11. Wilcox, D.A., Rosenberg, J.B., Johnson, B.D., and Montgomery, R.R. Storage of factor VIII (FVIII) in the alpha granules of human platelets following retroviral transduction and transplantation of human CD34+ cells into nod-scid mice, Blood. 96 a:3467, 2000.
12. Wilcox, D. A., Kiem, H.-P., Johnson, B.D., Nash, R.A., Catalfamo, J.L., and Boudreaux, M.K. Transgene expression targeted in canine megakaryocytes as a model for gene therapy of lineage-specific disorders, Thrombosis and Haemostasis. 86 a:5757, 2001.
13. Boudreaux, M.K., Niemeyer, G.P., Wilcox, D.A., Brawner, W.R., Lothrop, Jr., C.D. Correction of type I glanzmann's thrombathenia in great pyrenees dogs by nonmyeloablative marrow transplantation, Blood. 98 a:721, 2001.
14. Shi, Q., Fahs, S.A., Wilcox, D.A., Kroner, P.A., Montgomery, R.R. Endothelial, platelet, and hepatic-specific expression of human FVIII and the effect of von Willebrand factor, Blood. 100 a:1906, 2002.
15. Wilcox, D.A., Hodivala-Dilke, K.M., Johnson, B.D., Hynes, R.O., and White II , G.C. Lineage-Specific Correction of glanzmann thrombasthenia by expression of a functional hybrid murine-human IIb3 integrin complex on the surface of platelets of b3 knockout mice, Blood. 100 a:3419, 2002.
16. Wilcox, D.A., Targeting transgene expression in canine megkaryocytes derived from lentivirus-transduced G-CSF mobilized CD34+ peripheral blood cells, Blood. 100 a:1713, 2002.
17. Wilcox, D.A., Hodivala-Dilke, K.M., Johnson, B.D., Hynes, R.O.,White II , G.C. Therapeutic expression of a platelet-specific integrin, aIIbβ3, Molecular Therapy. 7 a:398, 2003.
18. Wilcox, D.A., Targeting transgene expression in canine megakaryocytes, Molecular Therapy. 7 a:1127, 2003.
19. Wilcox, D.A., Hodivala-Dilke, K.M., Johnson, B.D., Hynes, R.O., and White II , G.C. Lineage-Specific Correction of a hemorrhagic disorder affecting platelets: gene therapy for glanzmann thrombasthenia, Journal of Thrombosis and Haemostasis. 1 a:130, 2003.
20. Yarovoi, H., Kufrin, D., Eslin, D.E., Zhu, H., Camire, R. Wilcox, D., Montgomery, R.R., Kowalska, M.A., Poncz, M. A transgenic mouse model demonstrates the efficacy of factor FVIII ectopically expressed in platelets for Haemophilia A treatment. Journal of Thrombosis and Haemostasis. 1 a:131, 2003.
21. Wilcox, D.A., Shi, Q., Nurden, P., Haberichter, S.L., Rosenberg, J.B., Johnson, B.D., Nurden, A.T., White II, G.C., Montgomery, R.R. EM localization and agonist-induced release of human FVIII from megakaryocytes transduced with a FVIII transgene, Blood. 102 a:297, 2003.
22. Yarovoi, H., King, M., Eslin, D.E., Haberichter, S.L., Shi, Q., Kowalska, M.A., Wilcox, D., Sachais, B.S., Montgomery, R.R., , Poncz, M. Demonstration that platelet-expressed human B-domainless Factor VIII can ameliorate the bleeding diathesis in a murine model of Haemophilia A. Blood. 102 a:175, 2003.
23. Shi, Q., Wilcox, D.A., Morateck, P., Fahs, S.A., Kenny, D., Montgomery, R.R. Targeting platelet GPIb transgene expression to megakaryocytes using a lentiviral vector and its potential for gene therapy of bernard soulier syndrome, Blood. 102 a:1029, 2003.
24. Patel, M., Wilcox D.A.., Giddings, A.M., McKay, T.R., Olsen, J.C. Modification of HEK 293 Cell Integrin Expression Profile Allows Convenient Large-Scale Roller Bottle Production of Lentiviral Vectors, Molecular Therapy. 9 a:81, 2004.
25. Du, L.M., Wilcox, D.A. Gene Therapy for Platelet Disorders: Targeting Transgene Expression in Canine Platelets, Molecular Therapy. 9 a:919, 2004.
26. Fang, J, Johnson, B.D., Wilcox, D.A. Assessing the Risk from Transfer of an Integrin β3 Gene that Encodes a Naturally Occurring Polymorphism Associated with Acute Coronary Thrombosis, Molecular Therapy. 9, a:920, 2004.
27. Yoshida, T., Gomez, J., Gama, V., Wickramasekera, N.T., Wilcox, D.A., Matsuyama, S. Bax inhibiting peptides (BIPs) derived from Ku70 suppress chemotherapy induced-cell death of megakaryoocytes, Blood. 104, a:1262, 2004.
28. Shi, Q., Wilcox, D.A., Fahs, S.A., Fang J, Johnson, B.D., Weiler, H., Montgomery, R.R. Lentivirus-Mediated Platelet-Specific Gene Therapy for Hemophilia A, Blood. 104, a:2974, 2004.
29. Wilcox, D.A., Fang, J., Du, L.M., and Boudreaux, M.K. Drug-selectable as well as therapeutic gene transfer into hematopoietic stem cells may be essential for gene therapy of inherited bleeding disorders in large animals, Molecular Therapy. 11, a:340, 2005.
30. Wilcox, D.A., Fang, J., Johnson, B.D., Valentin, N. Modulating murine platelet function by expressing integrin αIIbβ3 locked-in its high affinity state, Journal of Thrombosis and Haemostasis. 3 a:OR108, 2005.
31. Boylan, B., Wilcox, D.A., Newman, D.K., Kahn, M.L., Newman, P.J. Immunodepletion of GPVI from human platelets circulating in NOD/SCID mice: development of a novel animal model for evaluating the therapeutic efficacy of compounds that affect human platelet function and survival, Journal of Thrombosis and Haemostasis. 3 a:OR284, 2005.
32. Shi, Q., Wilcox, D.A., Fahs, S.A., Weiler, H., Montgomery, R.R. Platelet-derived factor VIII (FVIII) is protected from inhibitor inactivation - an approach for gene therapy of hemophilia A even in the presence of FVIII inhibitors, Journal of Thrombosis and Haemostasis. 3 a:H05, 2005.
33. Shi, Q., Wilcox, D.A., Fahs, S.A., Fang J, Johnson, B.D., Weiler, H., Montgomery, R.R. Murine hemophilia A is phenotypically corrected by platelet-expressed factor VIII even in the absence of detectable plasma FVIII, Journal of Thrombosis and Haemostasis. 3 a:OR186, 2005.
34. Wilcox, D.A., Fang, J., Lily M. Du, L.M., and Boudreaux, M.K. Phenotypic correction of a canine model for glanzmann thrombasthenia demonstrates efficacy for using platelets to deliver therapeutics at the site of vascular injury, Blood. 106, a:3045, 2005.
35. Wilcox, D.A., Therapeutic expression of IIb3 in murine and canine models of glanzmann thrombasthenia, Subcommittee Meeting on Platelets, Annual Meeting of the American Society of Hematology, Atlanta, GA, Blood. 106, Invited Presentation, 2005.
36. Shi, Q., Wilcox, D.A., Fahs, S.A., Cooley, B.C., Desai, D., Weiler, H., Morateck, P.A., Montgomery, R.R. Platelet-derived factor VIII (FVIII) corrects the murine hemophilia A phenotype even in the presence of FVIII inhibitors, Blood. 106, a:457, 2005.
37. Wilcox, D.A., Gene therapy for inherited platelet bleeding disorders, Annual Conference of the Haematology Society of Australia and New Zealand, Hobart, Tasmania, (Invited Presentation), October 15-18 2006.
38. Wilcox, D.A., Targeting Coagulation Factor VIII to platelets for gene therapy of Hemophilia A, Annual Conference of the Haematology Society of Australia and New Zealand, Hobart, Tasmania, (Invited Presentation), October 15-18 2006.
39. Fang, J., Jensen, E.S., Du, L.M., Boudreaux, M.K., Wilcox, D.A., Intravenous immunoglobulin (IVIG) diminishes immune-mediated clearance of platelets expressing an integrin IIb3 transgene product that restores hemostasis in a canine model for Glanzmann Thrombasthenia, Blood. 108, a:3263, 2006.
40. Shi, Q., Fahs, S.A., Wilcox, D.A., Weiler, H., Haberichter, S.L., Montgomery, R.R., Endothelial and Platelet FVIII/VWF Expression - Divergence in Clinical Effect in Murine Models of Hemophilia A with and without FVIII Inhibitory Antibodies, Blood. 108, a:3286, 2006.
41. Wilcox, D.A., Fang, J., Jensen, E.S., Du, L.M., and Boudreaux, M.K. Thereapeutic expression of a platelet-specific integrin restores hemostasis in dogs with glanzmann thrombasthenia, Molecular Therapy. , a:767, 2007.
42. Shi, Q., Fahs, S.A., Wilcox, D.A., Morateck, P.A., Montgomery, R.R. Transplant bone marrow that is genetically modified to express FVIII only in platelets can restore hemostasis to hemophilia A mice on a strong inhibitor background, Journal of Thrombosis and Haemostasis. a:P-W-232, 2007.
43. Ghevaert C., Wilcox, D.A., Fang, J., Ouwehand, W.H., Williamson, L.M. Recombinant human HPA-1A antibodies for treatment of feto-maternal allo-immune thrombocytopenia (FMAIT): proof of principle in an in vivo murine model, Journal of Thrombosis and Haemostasis. a:O-T-025, 2007.
44. Wilcox, D.A., Fang, J., Jensen, E.S., Du, L.M., and Boudreaux, M.K. Correction of haemorrhagic disorders affecting platelets: gene therapy restores hemostasis within a canine model for glanzmann thrombasthenia, Journal of Thrombosis and Haemostasis. a:O-S-024, 2007.
45. Qizhen Shi, Scot A Fahs, David A Wilcox, Erin L Kuether, Hartmut Weiler and Robert R Montgomery. In the Presence of Pre-existing Factor VIII (FVIII) Immunity, Hematopoietic Stem Cells (HSC) that Are Genetically Modified to Express FVIII in Platelets Were Successfully Transplanted into Hemophilic Mice Under Myeloablative and Various Non-myeloablative Conditions, Blood. a: 768, 2007.
46. Gomez JA, Gama V, Yoshida T, Stapleton M, Paddock C, Wilcox D, Newman P, Matsuyama S, Blockade of chemotherapy-induced thrombocytopenia by Bax Inhibiting Peptides (BIPs) in mouse model. Blood, a:281 2007.
47. David A. Wilcox, Juan Fang Eric S. Jensen, Lily M. Du, Mary K. Boudreaux. Hematopoietic stem cell gene therapy for inherited platelet bleeding disorders, Blood Cells, Molecules, and Diseases. 40,(2) a:291, 2008.
48. Ghevaert C., Wilcox, D.A., Fang, J., Armour, K.L., Clark, M.R., Ouwehand, W.H., Williamson, L.M. Recombinant Human HPA-1A Antibodies for Treatment of Fetomaternal AlloimmuneThrombocytopenia (FMAIT) : Proof of Principle in an in Vivo Murine Model and Human Volunteer Studies. Blood a:85, 2008.
49. Wilcox, D.A., Fang, J., North, P., Nurden P., Nurden A.T., Valentin, N. High Mortality in Mice with Platelets Expressing Integrin αIIbβ3 Locked-In Its High Affinity State, Blood a:1832, 2008.
50. David A. Wilcox, Lily M. Du, Sandra L. Haberichter, Paula M. Jacobi, Juan Fang, Eric S. Jensen, Qizhen Shi and Robert R. Montgomery. Platelet Targeted Expression of Coagulation Factor VIII (FVIII) Shows efficacy for using the dog as a large animal model for gene therapy of hemophilia A. Blood a:3525, 2008.
51. D.A. Wilcox, J. Fang, P. North, P. Nurden, A.T. Nurden, N. Valentin. There is a high mortality rate in mice when platelet integrin alphaIIbbeta3 is locked-in its high affinity state, J Thromb Haemost, 7, a:OC-TH-097, 2009.
52. C. Gao, B. Boylan, J. Fang, D.A. Wilcox, D.K. Newman, P.J. Newman. Antibody-independent, αIIbβ3-mediated activation of human platelets by unfractionated heparin, J Thromb Haemost, 7, a:AS-TH-009, 2009.
53. Qizhen Shi, Erin L. Kuether, Scot A. Fahs, Jocelyn Schroeder, David A. Wilcox, and Robert R. Montgomery. Sustained phenotypic correction of murine hemophilia A with pre-existing anti-FVIII immunity using lentivirus-mediated platelet-specific FVIII gene transfer. (Oral Presentation). Blood a:29, 2009.
54. Lily M. Du, Timothy C. Nichols, Sandra L. Haberichter, Paula M. Jacobi, Eric S. Jensen, Juan Fang, Qizhen Shi, Robert R. Montgomery, and David A. Wilcox. Platelet-Targeted Expression of Human BDD-FVIII Reduces Bleeding in Canine Hemophilia A. (Oral Presentation). Blood a:691, 2009.
55. Qizhen Shi, Erin L. Kuether, Jocelyn A. Schroeder, Scot A. Fahs, David A. Wilcox, and Robert R. Montgomery. The Important Role of Von Willebrand Factor In Platelet-Derived FVIII Gene Therapy of Murine Hemophilia A In The Presence of Inhibitors. Blood a:2201, 2010
56. Lily M. Du, Helen W.G. Franck, Elizabeth P. Merricks, Paquita Nurden, Eric S. Jensen, Sandra L. Haberichter, Troy B. Hawkins, Paula M. Jacobi, Juan Fang, Sevasti B. Koukouritaki, Alan T. Nurden, Qizhen Shi, Robert R. Montgomery, and David A. Wilcox. De novo synthesis & storage of Human FVIII in platelets reduces bleeding in canine Hemophilia A. Blood a:2198, 2010.
57. Lily M. Du, Helen W.G. Franck, Elizabeth P. Merricks, Paquita Nurden, Eric S. Jensen, Sandra L. Haberichter, Troy B. Hawkins, Paula M. Jacobi, Juan Fang, Sevasti B. Koukouritaki, Alan T. Nurden, Qizhen Shi, Robert R. Montgomery, and David A. Wilcox. Gene therapy targeting synthesis of coagulation factor viii in platelets reduces bleeding in canine hemophilia a. Awarded Best Abstract in Basic Research to be presented at the American Society for Bone Marrow Transplant, Hawaii a:3, Feb 19, 2011.